Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,897,576
  • Shares Outstanding, K 1,300,260
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.19
  • Price/Sales 3.37
  • Price/Cash Flow 7.02
  • Price/Book 4.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.27 +5.83%
on 05/03/18
75.92 -10.41%
on 04/19/18
-7.66 (-10.12%)
since 04/18/18
3-Month
64.27 +5.83%
on 05/03/18
82.71 -17.77%
on 03/13/18
-12.68 (-15.71%)
since 02/16/18
52-Week
63.76 +6.68%
on 06/16/17
89.54 -24.03%
on 01/29/18
+3.59 (+5.57%)
since 05/18/17

Most Recent Stories

More News
U.S. Food and Drug Administration Approves Expanded Indication for Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate...

GILD : 68.02 (+0.62%)
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO...

GILD : 68.02 (+0.62%)
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory,...

ALPN : 9.95 (+12.94%)
GILD : 68.02 (+0.62%)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.66%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $66.19 to a high of $67.68. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of...

GILD : 68.02 (+0.62%)
Gilead Sciences (GILD) Breaks Through Resistance at $66.99

Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $65.92 today and have reached the first resistance level of $66.99. Analysts will be watching for a cross of the next upside...

GILD : 68.02 (+0.62%)
Harish Manwani Joins Gilead Sciences' Board of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M. Manwani has been appointed to the company's Board of Directors.

QCOM : 57.51 (+0.98%)
GILD : 68.02 (+0.62%)
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.

NVS : 77.06 (-0.12%)
EXEL : 21.58 (+0.09%)
GILD : 68.02 (+0.62%)
ICPT : 72.45 (+1.74%)
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead's Chief Scientific...

GILD : 68.02 (+0.62%)
Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space?

Many investors missed the trend when Chinese pharmaceutical companies got hot. Many of these stocks are up 3-fold or more in the last year as Chinese biotechnology companies have played catch-up to U.S....

CRSP : 64.68 (-1.10%)
BGNE : 194.55 (+2.88%)
GNNSF : 4.0000 (+12.68%)
GILD : 68.02 (+0.62%)
The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate

The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate

EPD : 28.02 (-0.39%)
CL : 62.22 (-0.11%)
GILD : 68.02 (+0.62%)
BP : 47.38 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 69.10
1st Resistance Point 68.56
Last Price 68.02
1st Support Level 67.41
2nd Support Level 66.80

See More

52-Week High 89.54
Fibonacci 61.8% 79.69
Fibonacci 50% 76.65
Fibonacci 38.2% 73.61
Last Price 68.02
52-Week Low 63.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar